NewsRx

Search our medical news database

Melanoma

Preliminary Data Show Immunogene Therapy is Safe

Published in Gene Therapy Weekly, September 14th, 2000

Preliminary data from an ongoing Phase I clinical trial of immunogene therapy in melanoma patients suggest that the procedure is feasible and safe.

"Dendritic cells (DCs) are potent antigen-presenting cells (APCs), and are being intensively studied as promising vehicles for the specific induction of anti-tumor immunity," reported Frank G. Haluska and colleagues from the Massachusetts General Hospital, Dana-Farber Cancer Institute, and Genzyme Molecular Oncology, Massachusetts. "Our own preclinical murine studies demonstrate that genetic modification of DCs produce APCs highly efficient in the stimulation of immunity against tumor antigens."

Haluska...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook